<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04200768</url>
  </required_header>
  <id_info>
    <org_study_id>S63330</org_study_id>
    <nct_id>NCT04200768</nct_id>
  </id_info>
  <brief_title>FATLAS: Comprehensive Multi-level Characterization of Systemic and Mammary Adiposity in Breast Cancer Patients.</brief_title>
  <acronym>FATLAS</acronym>
  <official_title>FATLAS: Comprehensive Multi-level Characterization of Systemic and Mammary Adiposity in Breast Cancer Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KU Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      FATLAS is a prospective, interventional, non Investigational Medicinal Product (IMP) study&#xD;
      aiming to characterize the micro- and macroenvironment of breast cancer according to patient&#xD;
      adiposity in different histological and molecular subtypes.&#xD;
&#xD;
      The macroscopic profiling of the patient's adiposity will be based on Body Mass Index (BMI),&#xD;
      bioimpedance analysis and waist-to-hip ratio. Blood samples will be taken for lipidomic&#xD;
      analyses and for hormonal and immuno assays. Microscopic profiling of adiposity and&#xD;
      inflammation will be done on fresh frozen (FF) and Formalin-Fixed Paraffin-Embedded (FFPE)&#xD;
      samples from the tumour resection specimen and will consist of histological characterization,&#xD;
      immuno assays, multiplex immunohistochemistry, DNA sequencing and single nuclei RNA&#xD;
      sequencing both in the tumour and in adjacent normal mammary tissue.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BMI</measure>
    <time_frame>Before surgery</time_frame>
    <description>Calculated: body mass (kg) divided by height squared (m²)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lipid levels in plasma</measure>
    <time_frame>Before surgery</time_frame>
    <description>Lipidomic analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Up- or downregulation of pathways on single cell level</measure>
    <time_frame>At surgery</time_frame>
    <description>Single nucleus RNA sequencing using 10X Genomics Platform after dissociation of tissue into single nuclei</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T cell repertoire</measure>
    <time_frame>At surgery</time_frame>
    <description>Number of T-cells per population using immunohistochemical phenotypic markers of cell type and of exhaustion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical activity level</measure>
    <time_frame>Before surgery</time_frame>
    <description>Time of activity of different intensities and time of sedentarity, evaluated using the Global Physical Activity Questionnaire (GPAQ) of the World Health Organisation (WHO) (scale: minutes per day, range [0 - 1440]). The higher the score for activity the better, the lower the score for sedentarity the better.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sleep behaviour score</measure>
    <time_frame>Before surgery</time_frame>
    <description>Pittsburgh Sleep Quality Index (PSQI) score (range: [0 - 21]). Higher scores indicate worse sleep quality.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dietary Quality Index</measure>
    <time_frame>Before surgery</time_frame>
    <description>Nutritional score (natural number, range [0 - 100]) calculated using the in-house Food Frequency Questionnaire. A score of &gt; 70 indicates healthy dietary behaviour.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dietary Food Intake</measure>
    <time_frame>Before surgery</time_frame>
    <description>Food intake in kcal per day calculated using the in-house Food Frequency Questionnaire.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fat percentage</measure>
    <time_frame>Before surgery</time_frame>
    <description>Calculated from multiple frequency bio-impedance measurements (in %, range [0 - 100]).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Waist-to-hip ratio</measure>
    <time_frame>Before surgery</time_frame>
    <description>Waist circumference (cm) divided by hip circumference (cm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Handgrip strength</measure>
    <time_frame>Before surgery</time_frame>
    <description>In kilograms (kg), measured by handheld dynamometer.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Prospective data and sample collection</intervention_name>
    <description>Performance of measurements of adiposity, extra collection of blood samples</description>
    <arm_group_label>Standard</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inclusion of 30 lean (BMI 18.5 - 24.9 kg/m²), 30 overweight (BMI 25 - 29.9 kg/m²), and 30&#xD;
        obese (BMI ≥ 30 kg/m²) patients with histological confirmation of Invasive Ductal Carcinoma&#xD;
        (IDC) on core diagnostic biopsy; 5 lean, 5 overweight and 5 obese Inflammatory Breast&#xD;
        Cancer (IBC) patients; 15 lean, 15 overweight and 15 obese patients with histological&#xD;
        confirmation of Invasive Lobular Carcinoma (ILC) on core diagnostic biopsy and 20 male&#xD;
        subjects with any type of breast cancer that meet following criteria:&#xD;
&#xD;
          -  be willing and able to provide written informed consent for this study;&#xD;
&#xD;
          -  be willing to provide plasma/blood and tissue samples;&#xD;
&#xD;
          -  be willing to have clinical measures of adiposity taken;&#xD;
&#xD;
          -  have stage I, II or III disease (so non-metastatic) with any clinical lymph node&#xD;
             status;&#xD;
&#xD;
          -  be scheduled for surgical resection of the tumour in UZ Leuven.&#xD;
&#xD;
          -  have a tumour size of ≥ 1.5 cm in order to have sufficient tumour material for the&#xD;
             biomarker analysis. Exceptions will be made for IBC patients, as in some cases no&#xD;
             residual tumour will be found after neoadjuvant treatment;&#xD;
&#xD;
          -  be treatment naïve, i.e. not having received systemic breast cancer treatment prior to&#xD;
             surgery. An exception is made for the IBC patients, as they will often have received&#xD;
             first line neoadjuvant chemotherapy before surgery. IBC patients that do not undergo&#xD;
             surgery after neoadjuvant treatment (e.g. because of inoperability of the patient)&#xD;
             will not be included;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy at time of diagnosis;&#xD;
&#xD;
          -  personal history of breast cancer (relapse/second primary);&#xD;
&#xD;
          -  mixed invasive tumour type on core biopsy or special type of breast carcinoma beside&#xD;
             pure ILC;&#xD;
&#xD;
          -  history of an additional malignancy that is progressing or that has required active&#xD;
             treatment in the 5 years prior to breast cancer diagnosis. Exceptions include basal&#xD;
             cell carcinoma of the skin or squamous cell carcinoma of the skin that have undergone&#xD;
             potentially curative therapy or in situ cervical cancer;&#xD;
&#xD;
          -  presence of an immune dysregulatory disease or condition which requires active immune&#xD;
             modulatory treatment of any kind, or has required treatment in the past two years.&#xD;
             Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid&#xD;
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a&#xD;
             form of systemic treatment;&#xD;
&#xD;
          -  history or current evidence of any condition, therapy, or laboratory abnormality that&#xD;
             might confound the results of the trial in the opinion of the treating investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marion Maetens, PhD</last_name>
    <phone>+3216321194</phone>
    <email>marion.maetens@kuleuven.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marion Maetens, PhD</last_name>
      <phone>+3216321194</phone>
      <email>marion.maetens@kuleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>Tatjana Geukens, MD</last_name>
      <phone>+3216321194</phone>
      <email>tatjana.geukens@kuleuven.be</email>
    </contact_backup>
    <investigator>
      <last_name>Christine Desmedt, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giuseppe Floris, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 21, 2019</study_first_submitted>
  <study_first_submitted_qc>December 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2019</study_first_posted>
  <last_update_submitted>November 2, 2020</last_update_submitted>
  <last_update_submitted_qc>November 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitaire Ziekenhuizen Leuven</investigator_affiliation>
    <investigator_full_name>Giuseppe Floris</investigator_full_name>
    <investigator_title>Breast Pathologist, Department of Pathology</investigator_title>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Body Mass Index</keyword>
  <keyword>Adiposity</keyword>
  <keyword>Obesity</keyword>
  <keyword>Inflammatory Breast Cancer</keyword>
  <keyword>Lobular Breast Cancer</keyword>
  <keyword>Tumour Microenvironment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

